Publications by authors named "Elena Efstathiou"
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures.
Mohammed Nabil Quraishi Jonathan Cheesbrough Peter Rimmer Benjamin H Mullish Naveen Sharma Elena Efstathiou
J Crohns Colitis
December 2024
Background: We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV) treatment, in primary sclerosing cholangitis associated inflammatory bowel disease (PSC-IBD); NCT05376228.
Method: Fifteen patients with PSC and active colitis (median faecal calprotectin 459µg/g; median total Mayo score 5) were treated with OV (125mg QID) for 4 weeks and followed-up for a further 4 weeks of treatment withdrawal (8 weeks, end-of-study). Colonic biopsies were obtained at baseline and week 4.
Article Synopsis
- The study investigates the presence of salivary antibodies against SARS-CoV-2 in healthcare workers, both after infection and vaccination, revealing that while serum antibodies are common, salivary antibodies are less prevalent and often non-neutralising.
- Serum samples showed a high prevalence of IgG antibodies after vaccination, but only a fraction also showed salivary antibodies, indicating a disconnect between systemic and mucosal immune responses.
- The findings emphasize the necessity for mucosal vaccines to improve oral and nasopharyngeal immunity, as salivary antibodies alone cannot reliably reflect overall antibody response from serum measurements.